Trial reportBMC anesthesiology2026
Effects of dexmedetomidine nasal spray combined with thoracic paravertebral block on sleep and pain in herpes zoster neuralgia: a randomized controlled trial.
Trial report in BMC anesthesiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHerpes zoster neuralgia(HZN) is a common challenging problem, and there is a growing need to develop safe and effective treatments. Sleep disorders is commonly associated with HZN because pain intensity of HZN conditions is often worse at night. Evidence indicates that dexmedetomidine nasal spray is effective in alleviating pain and improving sleep quality in perioperative patients; however, no randomized controlled trials have evaluated its use in HZN.
methodsIn this randomized, controlled, single-blind trial, a total of 103 patients were screened, and 70 patients were equally randomized to the dexmedetomidine(DEX) group and the control group. The DEX group received dexmedetomidine nasal spray at 1.0 ~ 1.5 µg·kg
resultsThe primary outcome was total sleep time during treatment. The group-by-time interaction for total sleep time was not statistically significant (F
conclusionsDexmedetomidine nasal spray effectively and safely improved sleep quality and alleviated pain in patients with truncal herpes zoster neuralgia. These findings need to be validated in multicenter studies in diverse populations to ensure generalizability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.